5 Cardio-oncology: Network-Based Prediction …
93
29. Cheng F, Liu C, Shen B, Zhao Z (2016) Investigating cellular network heterogeneity and
modularity in cancer, a network entropy and unbalanced motif approach. BMC Syst Biol
10(Suppl 3):65
30. Cheng F, Zhao J, Fooksa M, Zhao Z (2016) A network-based drug repositioning infrastructure
for precision cancer medicine through targeting significantly mutated genes in the human
cancer genomes. J Am Med Inform Assoc 23(4):681–691
31. Cheng F, Zhao J, Hanker AB, Brewer MR, Arteaga CL, Zhao Z (2016) Transcriptomeand proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways
altered by PIK3CA (H1047R) in HER2/ER-positive breast cancer. Breast Cancer Res Treat
160(3):457–474
32. Fang J, Cai C, Wang Q, Lin P, Zhao Z, Cheng F (2017) Systems pharmacology-based discovery
of natural products for precision oncology through targeting cancer mutated genes. CPT
Pharmacometrics Syst Pharmacol 6(3):177–187
33. Fang J, Liu C, Wang Q, Lin P, Cheng F (2018) In silico polypharmacology of natural products.
Brief Bioinform 19(6):1153–1171
34. Fang J, Wu Z, Cai C, Wang Q, Tang Y, Cheng F (2017) Quantitative and systems pharmacology.
1. In silico prediction of drug-target interactions of natural products enables new targeted
cancer therapy. J Chem Inf Model 57(11):2657–2671
35. Jiang X, Lu W, Shen X, Wang Q, Lv J, Liu M et al (2018) Repurposing sertraline sensitizes
non-small cell lung cancer cells to erlotinib by inducing autophagy. JCI Insight 3(11):e98921
36. Li J, Lei K, Wu Z, Li W, Liu G, Liu J et al (2016) Network-based identification of
microRNAs as potential pharmacogenomic biomarkers for anticancer drugs. Oncotarget
7(29):45584–45596
37. Lu W, Cheng F, Yan W, Li X, Yao X, Song W et al (2017) Selective targeting p53(WT)
lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA. Oncogene
36(33):4719–4731
38. Shen Q, Cheng F, Song H, Lu W, Zhao J, An X et al (2017) Proteome-scale investigation of
protein allosteric regulation perturbed by somatic mutations in 7000 cancer genomes. Am J
Hum Genet 100(1):5–20
39. Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W et al (2016) Suppression of KRas-mutant cancer
through the combined inhibition of KRAS with PLK1 and ROCK. Nat Commun 7:11363
40. Wu D, Wang W, Chen W, Lian F, Lang L, Huang Y et al (2018) Pharmacologic inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid
leukemia cells. Haematologica 103(9):1472–1483
41. Wu Z, Cheng F, Li J, Li W, Liu G, Tang Y (2017) SDTNBI, an integrated network and
chemoinformatics tool for systematic prediction of drug-target interactions and drug repositioning. Brief Bioinform 18(2):333–347
42. Wu Z, Lu W, Yu W, Wang T, Li W, Liu G et al (2018) Quantitative and systems pharmacology 2. In silico polypharmacology of G protein-coupled receptor ligands via network-based
approaches. Pharmacol Res 129:400–413
43. Wu Z, Lu W, Wu D, Luo A, Bian H, Li J et al (2016) In silico prediction of chemical
mechanism of action via an improved network-based inference method. Br J Pharmacol
173(23):3372–3385
44. Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y et al (2017) Inhibition of histone deacetylases
sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib
in vitro and in vivo. Br J Pharmacol 174(20):3608–3622
45. Zhao J, Cheng F, Wang Y, Arteaga CL, Zhao Z (2016) Systematic prioritization of druggable
mutations in approximately 5000 genomes across 16 cancer types using a structural genomicsbased approach. Mol Cell Proteomics 15(2):642–656
46. Zhao J, Cheng F, Zhao Z (2017) Tissue-specific signaling networks rewired by major
somatic mutations in human cancer revealed by proteome-wide discovery. Cancer Res
77(11):2810–2821
47. Zhao Y, Hu Q, Cheng F, Su N, Wang A, Zou Y et al (2015) SoNar, a highly responsive
NAD+/NADH sensor, allows high-throughput metabolic screening of anti-tumor agents. Cell
Metab 21(5):777–789
93
29. Cheng F, Liu C, Shen B, Zhao Z (2016) Investigating cellular network heterogeneity and
modularity in cancer, a network entropy and unbalanced motif approach. BMC Syst Biol
10(Suppl 3):65
30. Cheng F, Zhao J, Fooksa M, Zhao Z (2016) A network-based drug repositioning infrastructure
for precision cancer medicine through targeting significantly mutated genes in the human
cancer genomes. J Am Med Inform Assoc 23(4):681–691
31. Cheng F, Zhao J, Hanker AB, Brewer MR, Arteaga CL, Zhao Z (2016) Transcriptomeand proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways
altered by PIK3CA (H1047R) in HER2/ER-positive breast cancer. Breast Cancer Res Treat
160(3):457–474
32. Fang J, Cai C, Wang Q, Lin P, Zhao Z, Cheng F (2017) Systems pharmacology-based discovery
of natural products for precision oncology through targeting cancer mutated genes. CPT
Pharmacometrics Syst Pharmacol 6(3):177–187
33. Fang J, Liu C, Wang Q, Lin P, Cheng F (2018) In silico polypharmacology of natural products.
Brief Bioinform 19(6):1153–1171
34. Fang J, Wu Z, Cai C, Wang Q, Tang Y, Cheng F (2017) Quantitative and systems pharmacology.
1. In silico prediction of drug-target interactions of natural products enables new targeted
cancer therapy. J Chem Inf Model 57(11):2657–2671
35. Jiang X, Lu W, Shen X, Wang Q, Lv J, Liu M et al (2018) Repurposing sertraline sensitizes
non-small cell lung cancer cells to erlotinib by inducing autophagy. JCI Insight 3(11):e98921
36. Li J, Lei K, Wu Z, Li W, Liu G, Liu J et al (2016) Network-based identification of
microRNAs as potential pharmacogenomic biomarkers for anticancer drugs. Oncotarget
7(29):45584–45596
37. Lu W, Cheng F, Yan W, Li X, Yao X, Song W et al (2017) Selective targeting p53(WT)
lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA. Oncogene
36(33):4719–4731
38. Shen Q, Cheng F, Song H, Lu W, Zhao J, An X et al (2017) Proteome-scale investigation of
protein allosteric regulation perturbed by somatic mutations in 7000 cancer genomes. Am J
Hum Genet 100(1):5–20
39. Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W et al (2016) Suppression of KRas-mutant cancer
through the combined inhibition of KRAS with PLK1 and ROCK. Nat Commun 7:11363
40. Wu D, Wang W, Chen W, Lian F, Lang L, Huang Y et al (2018) Pharmacologic inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid
leukemia cells. Haematologica 103(9):1472–1483
41. Wu Z, Cheng F, Li J, Li W, Liu G, Tang Y (2017) SDTNBI, an integrated network and
chemoinformatics tool for systematic prediction of drug-target interactions and drug repositioning. Brief Bioinform 18(2):333–347
42. Wu Z, Lu W, Yu W, Wang T, Li W, Liu G et al (2018) Quantitative and systems pharmacology 2. In silico polypharmacology of G protein-coupled receptor ligands via network-based
approaches. Pharmacol Res 129:400–413
43. Wu Z, Lu W, Wu D, Luo A, Bian H, Li J et al (2016) In silico prediction of chemical
mechanism of action via an improved network-based inference method. Br J Pharmacol
173(23):3372–3385
44. Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y et al (2017) Inhibition of histone deacetylases
sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib
in vitro and in vivo. Br J Pharmacol 174(20):3608–3622
45. Zhao J, Cheng F, Wang Y, Arteaga CL, Zhao Z (2016) Systematic prioritization of druggable
mutations in approximately 5000 genomes across 16 cancer types using a structural genomicsbased approach. Mol Cell Proteomics 15(2):642–656
46. Zhao J, Cheng F, Zhao Z (2017) Tissue-specific signaling networks rewired by major
somatic mutations in human cancer revealed by proteome-wide discovery. Cancer Res
77(11):2810–2821
47. Zhao Y, Hu Q, Cheng F, Su N, Wang A, Zou Y et al (2015) SoNar, a highly responsive
NAD+/NADH sensor, allows high-throughput metabolic screening of anti-tumor agents. Cell
Metab 21(5):777–789